Characterization of the Pall Celeris system as a point-of-care device for therapeutic angiogenesis

Cytotherapy. 2015 Sep;17(9):1302-13. doi: 10.1016/j.jcyt.2015.04.006. Epub 2015 May 30.

Abstract

Background aims: The Pall Celeris system is a filtration-based point-of-care device designed to obtain a high concentrate of peripheral blood total nucleated cells (PB-TNCs). We have characterized the Pall Celeris-derived TNCs for their in vitro and in vivo angiogenic potency.

Methods: PB-TNCs isolated from healthy donors were characterized through the use of flow cytometry and functional assays, aiming to assess migratory capacity, ability to form capillary-like structures, endothelial trans-differentiation and paracrine factor secretion. In a hind limb ischemia mouse model, we evaluated perfusion immediately and 7 days after surgery, along with capillary, arteriole and regenerative fiber density and local bio-distribution.

Results: Human PB-TNCs isolated by use of the Pall Celeris filtration system were shown to secrete a panel of angiogenic factors and migrate in response to vascular endothelial growth factor and stromal-derived factor-1 stimuli. Moreover, after injection in a mouse model of hind limb ischemia, PB-TNCs induced neovascularization by increasing capillary, arteriole and regenerative fiber numbers, with human cells detected in murine tissue up to 7 days after ischemia.

Conclusions: The Pall Celeris system may represent a novel, effective and reliable point-of-care device to obtain a PB-derived cell product with adequate potency for therapeutic angiogenesis.

Keywords: angiogenesis; hind limb ischemia; peripheral blood cells; point-of-care.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Component Removal
  • Cell Differentiation
  • Cell Movement
  • Cell Separation / methods
  • Chemokine CXCL12 / metabolism
  • Disease Models, Animal
  • Endothelial Cells / cytology
  • Filtration
  • Flow Cytometry
  • Hindlimb / blood supply
  • Humans
  • Ischemia / therapy*
  • Leukocytes / immunology
  • Mice
  • Neovascularization, Physiologic*
  • Peripheral Arterial Disease / therapy*
  • Point-of-Care Systems*
  • Reperfusion
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Chemokine CXCL12
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A